Breast Cancer

Anastrozole benefits confirmed in postmenopausal breast cancer patients

Published in Biotech Business Week, January 10th, 2005

Postmenopausal women with hormone-sensitive breast cancer receive an increased benefit from treatment with the aromatase inhibitor anastrozole compared with tamoxifen, according to two papers presented at the 27th Annual San Antonio Breast Cancer Symposium.

Benefits were seen whether anastrozole was given as a primary treatment for 5 years, or as an additional treatment after 2 years of tamoxifen.

Aromatase inhibitors deplete circulating estrogen in postmenopausal women, shutting down the principal cell signaling pathway in the pathogenesis of breast cancer. Tamoxifen, in comparison, exerts its effect by interacting with the estrogen receptor.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2005-01-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry